Agilon Health Inc (AGL) (Q3 2026) Earnings Call Highlights: Guidance Raised as Adjusted
Agilon Health Inc (AGL) reported Q3 2026 earnings, beating guidance with adjusted EBITDA of $64M, up from -$91M in Q3 2025. The company raised full-year 2026 guidance and expects 40-50% ACO membership growth in 2027. However, Medicare Advantage membership declined 10% YoY, and medical costs remain high. The company plans to expand into new markets starting in 2028. AGL ended Q3 with $312M in cash and raised its year-end cash outlook to at least $175M.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance could attract buying, but cost and membership trends temper upside.
Market read
First report of Agilon Health's Q3 earnings and guidance lift; material for traders focused on health‑care stocks.
What to watch
Potential headwinds from slower external market expansion and modest 2027 contracting benefit.
Background
Agilon Health reported Q3 2026 results, exceeding guidance and raising full‑year outlook, while noting membership declines and cost pressures.
Ticker impact
Q3 2026 earnings beat and full-year guidance raised, with adjusted EBITDA of $64M versus -$91M a year earlier.
likely upward pressure as investors price in improved earnings and cash outlook
The company posted a material earnings beat and lifted cash outlook, which typically drives buying interest.
Market effects
Positive signal for the Medicare Advantage and ACO space, may lift peers.
U.S. healthcare services sector could see modest gains.
Limited to U.S. health‑care investors.
Counterpoint
Guidance may be optimistic given declining Medicare Advantage membership and high expense ratios.
Key entities
- ExecutiveTim O'Rourke
CEO who discussed growth timeline and pipeline.
- ExecutiveJeff Schwanecke
CFO who detailed cost trends and cash outlook.
